TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Gain in Lean Body Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of food on drug concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in alpha frequency band power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: serum antioxidant levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in serum concentrations of WBC count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in serum concentrations of RBC count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in serum concentrations of Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in serum concentrations of BUN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in serum concentrations of Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Response of Xerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cellular immune responses to vaccinia virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: blood and airway neutrophil population
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Progression-free Survival (PFS) at 3 Months
Endpoint domain: Mortality/survival
Primary endpoint: Serum Macrophage-Colony Stimulating Factor (M-CSF) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Success of colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportions of patients receiving adjuvant chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Direct healthcare costs of managing patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Discontinuation rates of adjuvant therapies
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of uremic pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in daytime PaCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum antibody responses to V cholerae LPS and CTB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mucosal responses to V cholerae LPS and CTB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Memory B and T cell responses to V cholerae LPS and CTB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC > 200 mg/dl and <70mg/dl during Marathon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time spent in hyper and hypoglycemia during Marathon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Coefficient of repeatability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall microbiome composition sampling gut
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in microbiome longitudinally
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Right ventricular end diastolic volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects With Clinically Significant Changes in Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in maximal isometric knee-extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Occurrence of Device-or Procedure-related Early and Late-onset of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From Recurrence of Symptomatic Atrial Fibrillation, Atrial Tachycardia or Atrial Flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: diagnostic MRI performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical inclination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cervical rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Test sit-and-reach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hospital Mortality to Day 90
Endpoint domain: Mortality/survival
Primary endpoint: complications post-ED visit
Endpoint domain: Adverse events/effects
Primary endpoint: diagnostic accuracy for hydronephrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in daily communication performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Ln Benzoylecgonine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to reach caloric goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in objective physical activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Nasotracheal Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety laboratory variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total mean PI (Plaque index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: undetectability of HBV DNA blood level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: P / F normalization times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Anti-Therapeutic Antibodies to Lebrikizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Glasgow Outcome Scale - Extended (GOSE)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in HgbA1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FSIGTT DI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary concentration of TIMP2-IGFBP7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemostatic effect for major bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mobility Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 12 Month NOSE Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Neurocognitive function changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with a score greater than 3/10 on PALLIA-10
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postoperative Pulmonary Complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Edema Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Number of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: cessation of convulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the serum concentration versus time curve (AUC) for folic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: biochemical Disease-Free Survival (bDFS)
Endpoint domain: Mortality/survival
Primary endpoint: Score of the SSS-CN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients with common founder mutations in known RP-related gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Genetic outcomes
Primary endpoint: Percent of patients with mutations in novel RP-related genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Genetic outcomes
Primary endpoint: Visual Analogue Scale (VAS) During Running Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total Score for Nasal Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Multiple Sleep Latency Test (MSLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Responders and Nonresponders According to Clinical Global Impression of Change (CGI-C) Ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety and Tolerability of MSC
Endpoint domain: Adverse events/effects
Primary endpoint: Regime Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Platelet counts of ≥ 100,000/mcL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum endocan level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants Considered Complete Responders
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Subjects With Major Pathologic Response (MPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cell-mediated Flu Vaccine Responses - inducible Granzyme B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Cell-mediated Flu Vaccine Responses - interferon(IFN)-γ/interleukin(IL)-10 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative incidence of Grade 3 and Grade 4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Microbiome Diversity in Fecal Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiome Richness in Fecal Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any untoward medical occurrence after fecal microbiota transplantation (FMT)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to measurement of the first trough tacrolimus blood concentration (C0) after conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Specificity, sensitivity, predictive values, and observer variation for scintigraphic procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood concentrations of vasoactive substances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clot size on scintigram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until desaturation from SpO2 100% to 95%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tolerable dose of MesoCancerVac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Release From Quarantine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Health Care Workers Who Developed SARS-COV-2 Infection
Endpoint domain: Adverse events/effects
Primary endpoint: sleep related breathing disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subjective understanding of disease and management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: C-reactive protein (CRP) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate haemostasis for chest closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: percent reduction of total acne lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durable response: platelet count of >=50 and <400 Gi/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Shoulder Pain And Disability Index (SPADI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario Shoulder Stability index (WOSI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective perception of shoulder improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sleep Stage Correlation
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Sensitivity on the Per Patient Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resolution of NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting plasma copeptin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean driving pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival at one year
Endpoint domain: Mortality/survival
Primary endpoint: Blood glucose incremental AUC 0-120 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Renal Hematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change on the Goal attainment scaling
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change on the Sensory Integration and Praxis Test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on the Chinese Sensory Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Plasma Concentration-Time Curve (AUC) from Time 0 to Time 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Plasma Concentration-Time Curve (AUC) from Time 0 to Time Infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Adhesion Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of FES-PET to visualize and quantify ER-positive lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in IIEF Erectile Function scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Knowledge Uptake
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline prevalence of Lymphatic Filariasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Objective tumor regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Parent-child Pairs Who Completed Study Sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Parent Satisfaction Assessed Via SATISFACTION SURVEY
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of estimated Glomerular Filtration Rate values within 30% of 'true' Glomerular Filtration Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Endodontic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microsphere Clearance Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microsphere Uptake Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rate 5 years after DFU diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Time to recover T4/T1 > 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity, specificity and likelihood ratios of DNA markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AUC of pioglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone reconstruction success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PHQ9 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sex hormone levels changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of Infection That Requires Removal of the Neurosurgical Device
Endpoint domain: Adverse events/effects
Primary endpoint: Target Vessel Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mini Examination of the Mental State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychiatric Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geriatric depression scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tinneti scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profiles of AZD7295
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability profiles of AZD7295
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Developing Diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported attitudes and behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Teacher reports of behaviors
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Parent reports of student behaviors
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Fecal immunochemical test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving 90% Improvement in PASI Score (PASI90) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving PASI90 at Week 44
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feeding Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Form 36 (SF-36) Physical Component Summary (PCS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short Form 36 (SF-36) Mental Component Summary (MCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: function reach test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in growth factors levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: BIS values during induction of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary atherosclerosis (Agatston Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Children's Hand-use Experience Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pediatric Quality of Life Inventory Generic Core Scales PedsQLTM 4.0
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in Hemoglobin status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in score on the Conners Abbreviated Symptom Questionnaire for Teachers (ASQ-T)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Perceived self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patients With FVIII Inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: American Shoulder and Elbow Score (ASES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vaginal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean percentage change in serum undercarboxylated osteocalcin (ucOC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean percentage change in UCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Preference for Insulin therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse events following DermaRep™ treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Factor VIII (FVIII) Inhibitor Development
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Less Than Expected Therapeutic Effects (LETE) in the On-Demand Setting
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With LETE in the Prophylaxis Setting
Endpoint domain: Adverse events/effects